| 1/8 | US=9 / Urologia Rosenberg J. Beyond Docetaxel: emerging agents in the treatment of advanced prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 147-51. ISBN 978-1-60327-831-7. DOCETAXEL; CANCER DE PROSTATA AVANCADO; INIBICAO DE MTOR; NOVAS TERAPEUTICAS; DESACETILACAO DAS HISTONAS; HSP90; FATOR 1 DE CRESCIMENTO COM INSULINA |
| 2/8 | US=6 / Quimioterapia Airley R. Targeting stress proteins: HSP90 inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 233-6. ISBN 978-0-470-09254-5. |
| 3/8 | US=35 / Biol/Mol Neckers L. Heat shock protein 90 and the proteasome: housekeeping proteins become novel molecular targets for cancer therapy. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 701-10. ISBN 978-1-4160-3703-3. PROTEINA DE CHOQUE TERMICO 90; PROTEASSOMA; ALVOS MOLECULARES; CANCER. TERAPIA; HSP90 |
| 4/8 | US=90 / Biol/Mol Xu W, Neckers L. EGFR signaling networks: differential dependence of EGFR and ErbB2 on the molecular chaperone Hsp90. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 63-71. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. CHAPERONES MOLECULARES; PROTEINA DE CHOQUE TERMICO 90; ANSAMICINAS BENZOQUINONA; GELDANAMICINA; HSP90 INIBIDOR; MUTACOES DE EGFR; SENSIBILIDADE AO FARMACO |
| 5/8 | US=46 / Câncer La Thangue NB. Theoretical foundations of cancer chemotherapy. In: Meyers RA. Cancer: from mechanisms to therapeutic approaches. New Jersey: Wiley-Blackwell, 2007. p. 369-87. ISBN 978-3-527-31768-4. CANCER; QUIMIOTERAPIA; DESENHO DE DROGAS; TERAPIA; P53; CICLO CELULAR; ANGIOGENESE; HSP90; ERB B; E2F |
| 6/8 | US=2-A / Biol/Mol Clarke PA, Powers M, Workman P. Molecular targets and therapeutics: inhibition of the molecular chaperone heat shock protein 90 in cancer: consequences for the regulation of survival signaling and induction of cell death. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 933-65. ISBN 978-3-527-31237-5. ALVOS MOLECULARES; TERAPEUTICA MOLECULAR; INIBICAO DA CHAPERONE; CHOQUE TERMICO 90; CANCER; REGULACAO DA SINALIZACAO; SOBREVIVENCIA; INDUCAO DE MORTE CELULAR; PROTEINA HSP90 |
| 7/8 | US=49-A / Câncer Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2006. p. 323-48. ISBN 978-0-12-006695-7. |
| 8/8 | US=507 / Tese/FAP Rodrigues BR. Regulação da atividade de STAT3 e o papel da proteína STI1/Hop secretada em glioblastoma. [Regulation of STAT3 activity and the role of secreted STI1/Hop in glioblastoma]. São Paulo, 2014. 47 p. Tese(Doutorado)-Fundação Antonio Prudente. Disponível em: http://accamargo.phlnet.com.br/Doutorado/2014/BrunaRoz/BrunaRoz.pdf GLIOBLASTOMA; ASTROCITOMA; FATOR DE TRANSCRICAO STAT3; EXOSSOMOS; STI1; HOP |
